1115.1000 -51.90 (-4.45%)
NSE Aug 01, 2025 15:31 PM
Volume: 103.7K
 

1115.10
-4.45%
ICICI Securities Limited
Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.
Tatva Chintan Pharma Chem Ltd. has gained 41.31% in the last 6 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended